GlassScriptPhysician profile
Colleen L Diering
NPI 1982722153
$12,959.81
in general payments reported to CMS, 2019-2025
23 companies · $6,240 in 2025
The $6,240 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,012 · 2022: $1,003 · 2023: $794 · 2024: $3,911 · 2025: $6,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,045 · Food and Beverage: $1,653 · Travel and Lodging: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,045.00 |
| Food and Beverage | $1,652.81 |
| Travel and Lodging | $246.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,395.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $379.74 | 2021-2025 | |
| Allergan, INC. | $182.97 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $134.46 | 2021-2023 | Austedo Xr |
| Pfizer INC. | $133.60 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $103.82 | 2022 | |
| Lilly USA, LLC | $79.15 | 2021-2023 | Emgality |
| Amgen INC. | $70.45 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $58.98 | 2023-2024 | Ztlido |
| Ucb, INC. | $55.64 | 2022-2024 | Briviact |
| Argenx US, INC. | $53.05 | 2022-2023 | Vyvgart |
| Biohaven Pharmaceuticals, INC. | $51.80 | 2021 | |
| Lundbeck LLC | $48.06 | 2022 | |
| Biogen, INC. | $36.58 | 2023 | Vumerity, Tysabri |
| Banner Life Sciences, LLC | $30.27 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21.99 | 2021 | |
| Emd Serono, INC. | $20.56 | 2023 | Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $20.39 | 2023 | |
| Neurelis, INC. | $19.76 | 2023 | Valtoco |
| Tanabe Pharma America, INC. | $16.78 | 2021 | |
| Csl Behring | $16.53 | 2023 | Hizentra |
| Currax Pharmaceuticals LLC | $15.90 | 2023 | Onzetra Xsail |
| Avanir Pharmaceuticals, INC. | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Diering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.